The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

Cancer Research

Volumn 62, Issue 17, 2002, Pages 5019-5026

  Lin, Boris ^a,b   Podar, Klaus ^a,b   Gupta, Deepak ^a,b   Tai, Yu Tzu ^a,b   Li, Sigui ^a   Weller, Edie ^a   Hideshima, Teru ^a,b   Lentzsch, Suzanne ^a,b   Davies, Faith ^a,b   Li, Cheng ^a   Weisberg, Ellen ^a   Schlossman, Robert L ^a,b   Richardson, Paul G ^a,b   Griffin, James D ^a,b   Wood, Jeanette ^c   Munshi, Nikhil C ^a,b   Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; PROTEIN TYROSINE KINASE INHIBITOR; THYMIDINE; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MICROENVIRONMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BONE MARROW; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; DEXAMETHASONE; DRUG SYNERGISM; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; PHOSPHORYLATION; PHTHALAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 0036731996     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
2. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
3. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment
4. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
5. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
6. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
7. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies
8. Prognostic value of bone marrow angiogenesis in multiple myeloma
9. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
10. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
11. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
12. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
13. Vascular endothelial growth factor (VEGF) triggers signaling cascades mediating multiple myeloma cell growth and migration
14. Vascular endothelial growth factor (VEGF)-induced migration of multiple myeloma cells is associated with β1-integrin- and P13-kinase-dependent PKCα activation
15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
16. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
17. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases
18. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
19. Isolation and characterization of human multiple myeloma cell enriched populations
20. Long-term culture of human bone marrow cells
21. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
22. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
23. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor
24. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data
25. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells
26. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB
27. Regulation of interleukin-6 in multiple myeloma and bone marrow stromal cells
28. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion
29. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
30. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
31. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma
32. Response of purified myeloma cells to hematopoietic growth factors
33. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6
34. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
35. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
36. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
37. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells